Jeffrey Tong

Partner at Third Rock Ventures

Menlo Park, California

Overview

Jeffrey Tong is currently a Partner at Third Rock Ventures in Menlo Park, California, with a strong background in the biotech sector and a focus on investing in various stages and sectors, including Series B, Series A, and Seed companies. With a PhD from Harvard University, Tong has held executive roles such as Executive Chairman at Delinia and President & CEO at Nora Therapeutics, and has made strategic investments in companies like Marea Therapeutics and Ambys Medicines.

Work Experience

Third Rock Ventures

Partner
2016 - Current
Focused on building innovative companies to serve patients with significant unmet medical needs. ARTBIO - Board member Asher Biotherapeutics - Board member Candid Therapeutics - Board member Marea Therapeutics - Board member Maze Therapeutics - Board member Rapport Therapeutics (RAPP) - Board member Septerna - Chairman of the board Past companies: Ambys Medicines Nurix (NRIX) Terremoto Biosciences

Delinia

Executive Chairman of the Board
2016 - 2017
Served as Executive Chairman and Chairman through $35M Series A financing and subsequent acquisition by Celgene for $775M with $300M upfront.